Enveric Biosciences Reports Financial Results and Provides Corporate Update for Second Quarter 2026

A welcome email is on its way. If you don't see it, please check your junk folder.

CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) (“Enveric” or the “Company”), a biotechnology company advancing next-generation neuroplastogenic small molecules to address psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2026, and provided a comprehensive business update.

“The second quarter was highlighted by important progress across the key activities supporting our planned first-in-human clinical trial of EB-003,” said Joseph Tucker, Ph.D., Chief Executive Officer of Enveric. “Over the past several months, we advanced multiple IND-enabling studies and generated additional preclinical data that support EB-003’s potential non-hallucinogenic profile. Collectively, these accomplishments strengthen the scientific foundation of our lead program as we work toward an IND submission for the anticipated Phase 1 trial.”

Dr. Tucker continued: “The additional preclinical data announced during the quarter are particularly encouraging because they provide further validation of our differentiated development strategy. Our previously reported BRET assay findings were reinforced by independent GloSensor™ assay data, extending the body of evidence supporting EB-003’s differentiated pharmacological profile and its potential to preserve certain therapeutic benefits associated with neuroplasticity while avoiding the hallucinogenic effects.”

“The broader neuroplastogenic field also continued to gain momentum during the quarter,” continued Dr. Tucker. “Recent FDA guidance addressing psychedelic drug development, together with strategic investment by major pharmaceutical companies, reflects increasing recognition of the therapeutic promise of these mechanisms. We believe these developments further support our long-held strategy of developing next-generation neuroplastogenic molecules intentionally designed to address many of the limitations associated with first-generation psychedelic-inspired therapies.”

Dr. Tucker added: “During the quarter, we also continued to expand Enveric’s intellectual property portfolio. We secured a new U.S. patent covering methods of treating psychiatric disorders using compounds from our EVM301 Series and subsequently received a Notice of Allowance for our EVM401 Series of proprietary methylone-inspired neuroplastogens. Together, these achievements reflect our ongoing commitment to building a broad portfolio of differentiated neuroplastogenic compounds.”

Dr. Tucker concluded: “As we enter the second half of 2026, our priorities remain clear: complete the remaining IND-enabling activities, submit our planned IND application, and advance EB-003 into a first-in-human clinical trial. We believe the progress over the past several months has strengthened both our lead development program and the broader Enveric platform, positioning the Company to continue creating long-term strategic and shareholder value.”